Background: We examined how prolonged antibiotic treatment affected the resistance and mutation frequency of human microflora isolated from intestine (Escherichia coli, enterococci spp.), pharynx (α-streptococci) and nostril (coagulase-negative staphylococci, CoNS).
Introduction
The human microflora constitutes a complex ecological system that plays an important role in human health, for example, by stimulating the immune response, aiding in the digestion of food and helping prevent pathogens from colonizing epithelial surfaces. Antimicrobial agents are known to influence the microflora and the extent of disturbance depends on a variety of factors, including drug dosage, route of administration and the pharmacokinetic/dynamic properties of the agent. 1 Even though the microflora may return to normal rapidly after completion of a treatment, long-term persistence (several years) of selected resistant commensal bacteria has been reported. 2 Such persistence and the natural exchange of genes between bacteria make the microflora a reservoir of resistance genes for potential spread to pathogens.
Bacteria with increased mutation rate, so-called mutators, have been found among pathogenic isolates of several bacterial species. 3, 4 For example, in Escherichia coli, Salmonella typhimurium, Helicobacter pylori and Pseudomonas aeruginosa between 1% and 36% of clinical isolates are mutators. [5] [6] [7] [8] *Corresponding author. Tel: +46-8-4572432; Fax: +46-8-301797; E-mail: dan.andersson@smi.ki.se described and their increase in mutation rates might vary between five-and 5000-fold. 9, 10 Whether an increased mutation rate is deleterious or beneficial depends on several factors, including the stability of the environment. Under constant conditions mutators are generally at a disadvantage because they generate deleterious mutations at a higher rate than a non-mutator. 11 In contrast, in a rapidly changing environment mutators might be selected because they have a higher probability of generating a beneficial mutation. 12 Thus, mutators are enriched because of the genetic linkage to the adaptive mutations they generate rather than as a direct result of their higher mutation rate. 11 Selection for mutators in pathogenic bacteria might occur because mutators increase the rate of, for example, antigenic surface variation or acquisition of antibiotic resistance. 13 Even though under laboratory conditions 14 and in animal models 12 selection for antibiotic resistance can rapidly enrich for mutators, it remains unclear whether clinical use of antibiotics is an important selector for strains with an increased mutation frequency. Recent work by Oliver et al. 6 showed that 36% of P. aeruginosa lung isolates from cystic fibrosis patients were mutators. Furthermore, there was a positive correlation between mutation rate and antibiotic resistance, suggesting that antibiotic use and associated selection for antibiotic resistance caused mutator enrichment. However, an alternative selective force that could have caused enrichment for mutators in this particular type of chronic infection was the continuous deterioration of the lung environment and the reiterated challenges by the host's immune system.
Thus, to examine a situation where the host environment is unaltered, and not directly affected by a current infectious pathogenesis, we examined whether extensive, high antibiotic use enriched for commensal bacteria with increased mutation frequency. The mutation frequency and resistance patterns were studied in E. coli, enterococci, α-streptococci and coagulase-negative staphylococci (CoNS) isolated from patient groups with high antibiotic use and a control group with no antibiotic exposure for the previous year.
Materials and methods

Subjects
Samples from nostril, pharynx and faeces were collected from patients at the Center of Cystic Fibrosis (n = 18), and Department of Haematology (n = 18) of the University Hospital, Uppsala, Sweden, subcultured within 24 h and then frozen at -70°C. Each patient's use of antibiotics during 1 year was recorded as the defined daily dose (DDD). 15 Primary health care patients (n = 30) with no antibiotic treatment for 1 year before sampling were used as controls. The age range, median and mean for the patients and controls were 2-77, 32 and 37 years and 33-77, 52 and 53 years, respectively. The ethics committee of the Faculty of Medicine at Uppsala University approved the study.
Bacteria
Three isolates of each bacterium were randomly chosen and verified. Faecal E. coli were isolated on CLED agar (cysteine lactose electrolyte deficient, brolacin agar; Merck, Darmstadt, Germany), incubated at 35°C, and verified by negative Voges-Proskauer test, urea and H 2 S, and positive indole reactions. Faecal enterococci were isolated on M-Enterococcus agar (Difco) as purple colonies and verified by positive aesculin (BBL Microbiology Systems) reactions. The α-streptococci from pharynx and CoNS from nostrils were isolated on blood agar plates (Columbia agar base with 5% horse blood; Acumedia Manufactures Inc., Baltimore, MD, USA) and incubated at 35°C in 5% CO 2 . α-Streptococci were verified by green haemolysis, negative optochin (Oxoid) and negative aesculin (BBL) tests. The CoNS were verified by a negative DNase test (Acumedia).
Susceptibilities and MIC
Antibiotic susceptibilities were determined by disc diffusion (Oxoid) on IsoSensitest agar (Oxoid) according to recommendations by the Swedish Reference Group for Antibiotics (available at www.srga.org). The antibiotics where chosen to represent the major classes. For those antibioticbacteria combinations lacking breakpoints the inhibition zone diameters were registered. MICs were determined by Etest (AB Biodisk, Solna, Sweden) on IsoSensitest agar according to the manufacturer's instructions.
Mutation frequency to rifampicin resistance
The mutation frequency to rifampicin resistance was calculated from 30 independent cultures (10 from each of the three isolates from each patient/control). The cultures were inoculated with 10 3 bacteria, from fresh broth preculture, in 0.4 mL Todd-Hewitt broth (Difco). The precultures were controlled for pre-existing mutants by plating 10 4 bacteria on blood agar plates containing rifampicin (Duchefa, Haarlem, The Netherlands) at a concentration of 50 mg/L for E. coli and enterococci, and 0.1 mg/L for α-streptococci and CoNS. If pre-existing mutants were found the test cultures were discarded (this was the case for one E. coli and two CoNS isolates). The cultures were incubated overnight at 35°C, giving 10 8-10 9 cfu/mL. The number of bacteria was determined by viable counts in 20 strains of E. coli, enterococci and CoNS, respectively. The optical density was also measured at 540 nm on all cultures. For the additional strains, the optical density was used to ensure that the cultures had reached maximal turbidity. To estimate the total number of bacteria the mean cfu/mL of the 20 viable counts were used. The number of α-streptococci was determined by viable count. Each culture was spread on a rifampicin-containing blood agar plate (50 mg/L for E. coli and enterococci or 0.1 mg/L for α-streptococci and CoNS). Different concentrations of rifampicin were used because of differences in intrinsic resistance between the bacteria. Plates were dried and incubated for 24 h and then colonies were counted. The mutation frequency for each isolate was determined from the median number of resistant mutants from the 10 cultures divided by the number of bacterial cells applied on the agar plates, and the geometric mean of the mutation frequency for the three isolates was calculated.
Mutation frequency to streptomycin resistance
The α-streptococci were also analysed for their mutation frequency to streptomycin resistance. Five independent cultures of one strain from each patient (n = 14) and controls (n = 17) were included. The remaining strains were excluded because of high initial MICs of streptomycin. Todd-Hewitt broth (50 mL) was inoculated with 10 3 bacteria from a fresh broth culture and incubated overnight at 35°C in 5% CO 2 . The number of bacteria was determined by viable count from one culture for each strain. The bacteria were concentrated by centrifugation and the resuspended pellet, ∼10 10 bacteria, was applied to blood agar plates containing 120 mg/L streptomycin (Duchefa) and then colonies were counted after 24 h.
Sequencing of the rpoB gene
The rpoB gene from four independent rifampicin-resistant colonies of enterococci, α-streptococci and CoNS was sequenced to verify that the resistant mutants had mutations in the rpoB gene. In E. coli rifampicin resistance is caused by rpoB mutations. 16 Primers for the β-subunit of rpoB were designed using Streptococcus pyogenes (GenBank accession number AJ295718) and Staphylococcus warneri (GenBank accession number AF325895) sequences. DNA was prepared with Dneasy Tissue kit (Qiagen). Five microlitres of sample was added to 45 µL PCR mixture, consisting of PCR buffer (Amersham Bioscience), 0.2 mmol/L deoxynucleostide triphosphate, 1 U Taq polymerase (Amersham Bioscience), and 2 pmol/µL of each primer. Amplification was performed in a thermal cycler (GeneAmp PCR system 9700; Applied Biosystems) with an initial denaturing step of 94°C for 5 min followed by 30 cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 30 s. An additional extension step of 72°C for 7 min completed the PCR. Negative controls were included and the reactions were evaluated in 1% agarose gel electrophoresis. The PCR products were sequenced by using ABI Prism BigDye terminator cycle sequencing ready reaction kit analysed in 310 Genetic Analyzer (Applied Biosystems) and compared with the original strains. All mutations were located within cluster I in the rpoB site as described in E. coli. 16 The enterococci had the substitutions Gly-522→Asp (GGT→GAT) or His-526→Arg (CAT→CGT). The α-streptococci showed similar point mutations at three sites in cluster I: Asp-516→Asn (GAC→AAC), Ser-522→Leu (TCA→TTA) or His-526→Tyr/Asn (CAC→TAC/AAC). In CoNS, two mutations were identified within cluster I: His-526→Tyr (CAC→TAC) and Ser-531→Phe (TCT→TTT).
Sequencing of the rpsL gene in α-streptococci
The rpsL gene from three independent streptomycin-resistant colonies of α-streptococci was sequenced to verify that the resistant mutants contained mutations in the rpsL gene, as has been shown in, for example, E. coli. 17 Primers were constructed from the rpsL gene of S. pyogenes (GenBank accession number AE006493). PCR and sequencing was performed as described above. All three strains had an A→T mutation that resulted in a Lys→Ile substitution at a position corresponding to codon 42 in E. coli. 17 
Statistical analysis
The statistical significance of the difference in mutation frequency was determined from the geometrical mean by Mann-Whitney test in Statistical Analyzing System version 8. Further comparison of mutation frequencies and total DDD was performed with Microsoft Excel.
Results
Distribution of antibiotic usage and antibiotic susceptibilities
The cystic fibrosis and haematology patients had a very high use of antibiotics during 1 year: on average 382 (range 36-1187) and 163 (range 30-535) DDDs, respectively (Figure 1 ). If neutropenic, the haematology patients received ciprofloxacin treatment, which reduced the probability of recovering E. coli from faeces. Thus, only five of 18 haematology patients had E. coli, whereas among cystic fibrosis patients 15/18 had E. coli. The number of strains from patients and controls are presented in Figure 2 . A clear shift towards increased resistance was seen among isolates from antibiotic-treated patients for practically all types of resistances examined (Figure 2 ). For example, the frequency of ciprofloxacin resistance in enterococci and CoNS was 63% and 67%, respectively, as compared with 0% in the controls. Similarly, the frequency of erythromycin-resistant CoNS was 52% in the patient group and 0% in the controls. Resistance to tobramycin was uncommon in E. coli and CoNS, in spite of a rather high use of tobramycin. Finally, vancomycin and imipenem resistance was not detected at all in the patient group, but these drugs were also the least used.
Mutation frequency
The frequency at which rifampicin-resistant mutants appear in vitro is often used as an indicator of the overall mutation frequency in bacteria. 8, 12 Rifampicin resistance in, for example, E. coli is caused by a limited number of mutations in the rpoB gene. We confirmed that this was the case also for the other commensals examined (see Materials and methods). The experimentally determined mutation frequencies to rifampicin resistance for each species are shown in Figure 3 (see Materials and methods). When comparing all isolates the mutation frequency to rifampicin resistance varied between 10 -9 and 10 -6 , and for each species there was a 10-to 100-fold range of frequencies. When comparing the patients and controls a significant difference in mutation frequency was noted for E. coli, enterococci and CoNS. Thus, the patients had commensal bacteria with a 3-, 1.8-and 1.5-fold higher mutation frequency as compared with the controls (P = 0.0001, 0.016 and 0.012, respectively). For α-streptococci, no significant difference (P = 0.74) in mutation frequency to rifampicin resistance between the controls and patients was evident. To further assess whether α-streptococci from patients had an increased mutation frequency, we also measured the mutation frequency to streptomycin resistance for this group of bacteria. The mutation frequency was 4.7 × 10 -10 and 1.5 × 10 -10 for patients and controls, respectively (P = 0.024), suggesting that strains with an increased mutation frequency might be enriched also in the α-streptococci. Why this difference was only seen for streptomycin resistance and not rifampicin is unclear, but might be related to which types of base pair substitutions cause resistance to the two antibiotics.
Mutation frequency in relation to the level of resistance to different antibiotic classes and DDD
We examined whether there was a correlation between the level of resistance to different antibiotic classes and the mutation frequency. For aminoglycosides, β-lactams, macrolides and trimethoprimsulfamethoxazole no correlation was observed (not shown). In contrast, when comparing ciprofloxacin-resistant and -susceptible isolates of E. coli within the patient group, the mutation frequencies differed significantly. Thus, ciprofloxacin-resistant E. coli showed a higher mutation frequency than the susceptible isolates (P = 0.036). Because of this observation the MICs of ciprofloxacin were determined for all strains of E. coli and enterococci from patients and controls. The MICs of ciprofloxacin for E. coli varied between 0.006 and >32 mg/L for patients and 0.004 and 0.016 mg/L for controls, and this difference was highly significant (P = 0.002). Similarly, the corresponding MICs of ciprofloxacin for enterococci were 0.38->32 mg/L for patients and 0.25-3 mg/L for controls (P = 0.0006). Furthermore, we examined whether antibiotic exposure (DDDs) was correlated with level of resistance or mutation frequency using linear regression. There was no correlation between total DDD of antibiotics and mutation frequency, nor between DDD of fluoroquinolones and ciprofloxacin resistance or mutation frequency. Finally, within each patient there was no correlation between the mutation frequencies for the different bacterial species.
Discussion
Theoretical considerations and experimental studies 12, 14, 18 show that mutators may be enriched when bacteria are exposed to a changing environment, e.g. repeated challenges of antibiotics, host immune responses or tissue damage caused by pathogenesis. Previous studies have concerned pathogenic bacteria. We wanted to study the impact of antibiotic use on the enrichment of mutators in the commensal microflora in order to reduce the likelihood that changes in the environmental conditions due to disease pathogenesis were the cause of selection for mutators. Thus, with regard to the microflora, antibiotic use was the primary selective parameter expected to vary between the patient and control groups. However, it should be noted that some of the haematology patients received cytostatic drugs that might disturb, for example, the local environment of the microflora or the host's immune response. When comparing bacterial isolates from the two groups studied, a significant increase of the geometric mean mutation frequency (two-to three-fold) was observed for E. coli, enterococci and CoNS isolated from the antibiotic use group. When examining the correlation between increased mutation frequency and resistance for each individual class of antibiotics, a significant correlation could only be seen for ciprofloxacin resistance where the resistant E. coli showed a higher mutation frequency than the susceptible isolates. A potential explanation for why only the faecal commensals showed this correlation could be that the faecal flora might be differently exposed to the drug than the pharynx and skin flora. Selection for resistant mutants requires a concentration interval 'selective window' 19 , where the concentration is high enough to prevent growth of the susceptible strain but low enough to allow growth of the resistant mutants. A substantial part of the fluoroquinolones in faeces is bound to various compounds, resulting in lower concentrations of active drug. 20 Furthermore, high free levels of fluoroquinolones have been found in sweat. 21 Thus, it is possible that in faeces there is a stronger selection for resistance (and mutators) than in sweat because the bacteria are exposed to the 'selective window' for a longer time period. 22, 23 Even though the increased mutation frequency in the patient group was significant, the magnitude of the increase was small. These increases could be caused by mutations of small effect in any of the processes that affect the mutation frequency in a bacterium (e.g. DNA polymerase, mismatch repair, excision repair, etc.). Unexpectedly, at least in the light of previous studies where frequencies of strong mutators were 1.2-36% 6,7 , only one such mutator (an E. coli from the patient group) was found among the 193 commensal isolates examined. One explanation for the rarity of strong mutators could be that for these investigated bacterial species, mutators are impaired for growth in the commensal flora of hosts, thereby preventing them increasing to a high frequency. 12 A second potential explanation is that putative mutator genes were removed by recombination after resistance was acquired. 24 Finally, a third possibility, and the one we find most likely, is that most of the antibiotics given to these patients are poor selectors of mutators. Thus, it is predicted that mutators are mainly enriched when the resistance is conferred by a chromosomal mutation (e.g. gyrA) that is formed at a higher rate in the mutator than the non-mutator. Most of the resistances in the examined bacteria result from genes that are located on horizontally transferred genetic elements (e.g. plasmids) and a mutator is not expected to increase the rate of plasmid transfer. The only exception is fluoroquinolone resistance, which is caused by sequential chromosomal mutations that confer stepwise increases in resistance. 25 Thus, acquiring high-level fluoroquinolone resistance is predicted to enrich for mutators. Support for this idea comes from the finding that a significant correlation between resistance and increased mutation frequency was only seen for ciprofloxacin.
The shift towards increased resistance among the patient isolates was pronounced. 26, 27 We cannot say whether the resistant clones were pre-existing in the individuals, selected de novo during treatment or acquired from other sources during hospitalization, but it is clear that the resistant strains were enriched during treatment to eventually dominate the microflora. It is likely that the selection and persistence of resistant commensal strains with an increased mutation rate constitutes a risk factor for additional resistance development, transfer of resistance to pathogens 24 and the occurrence of difficult-to-treat endogenous infections. Mutation frequencies to rifampicin resistance for four species of bacteria isolated from patients and controls. Each data point represents the mutation frequency of one bacterial species from one patient or control. The overall geometric mean mutation frequency for each bacterial species for the whole patient and control group is indicated by a line.
